Extended duration of the detectable stage by adding HPV test in cervical cancer screening

British Journal of Cancer

Volumn 89, Issue 10, 2003, Pages 1830-1833

  Van Den Akker van Marie, M E ^a   Van Ballegooijen, M ^a   Rozendaal, L ^b   Meijer, C J L M ^b   Habbema, J D F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer screening model; Human papillomavirus

Indexed keywords

ADULT; ARTICLE; CANCER RISK; CANCER SCREENING; CARCINOMA IN SITU; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; WART VIRUS;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; NEOPLASM STAGING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 0348013449     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601355     Document Type: Article

References (19)

1. Cuzick J (2000) Human papillomavirus testing for primary cervical cancer screening. JAMA 283: 108-109
2. Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorincz A, Chan WK, Krausz T, Soutter P (1999a) HPV testing in primary screening of older women. Br J Cancer 81: 554-558
3. Cuzick J, Sasieni P, Davies P, Adams J, Normand C, Frater A, van Ballegooijen M, van den Akker E (1999b) A systematic review of the role of human papillomavirus testing within a cervical screening programme. Health Techno/Assess 3(i-iv): 1-196
4. Evander M, Edlund K, Gustafsson A, Jonsson M, Karlsson R, Rylander E, Wadell G (1995) Human papillomavirus infection is transient in young women: a population-based cohort study. J Infect Dis 171: 1026-1030
5. Gustafsson L, Adami HO (1989) Natural history of cervical neoplasia: consistent results obtained by an identification technique [see comments]. Br J Cancer 60: 132-141
6. Ho GY, Palan PR, Basu J, Romney SL, Kadish AS, Mikhail M, Wassertheil-Smoller S, Runowicz C, Burk RD (1998) Viral characteristics of human papillomavirus infection and antioxidant levels as risk factors for cervical dysplasia. Int J Cancer 78: 594-599
7. Kim JJ, Wright TC, Goldie SJ (2002) Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance. JAMA 287; 2382-2390
8. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M (1999) Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 91: 954-960
9. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K (2002) Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287: 2372-2381
10. Meijer CJLM (1997) Human Papillomavirus and Cervical Cancer Screening: Epidemiological Aspects of HPV Infection of Normal Cervical Epithelium in Relation to the Development of Abnormal Cytology [in Dutch]. Amsterdam: Department of Pathology, University Hospital Vrije Universiteit
11. Meijer CJLM, Walboomers JMM (2000) Cervical cytology after 2000: where to go? J Clin Pathol 53: 41-43
12. Melkert PW, Hopman E, van den Brule AJ, Risse EK, van Diest PJ, Bleker OP, Helmerhorst T, Schipper ME, Meijer CJ, Walboomers JM (1993) Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer 53: 919-923
13. Myers ER, McCrory DC, Nanda K, Bastian L, Matchar DB (2000) Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 151: 1158-1171
14. Rozendaal L, Walboomers JM, van der Linden JC, Voorhorst FJ, Kenemans P, Helmerhorst TJ, van Ballegooijen M, Meijer CJ (1996) PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 68: 766-769
15. Rozendaal L, Westerga J, van der Linden JC, Walboomers JM, Voorhorst FJ, Risse EK, Boon ME, Meijer CJ (2000) PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 53: 606-611
16. van Oortmarssen GJ, Habbema JD (1991) Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer 64: 559-565
17. van Oortmarssen GJ, Habbema JD (1995) Duration of preclinical cervical cancer and reduction in incidence of invasive cancer following negative pap smears. Int J Epidemiol 24: 300-307
18. van Oortmarssen GJ, Habbema JD, van Ballegooijen M (1992) Predicting mortality from cervical cancer after negative smear test results. BMJ 305: 449-451
19. Zielinski GD, Snijders PJ, Rozendaal L, Voorhorst FJ, van der Linden HC, Runsink AP, de Schipper FA, Meijer CJ (2001) HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 85: 398-404